Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors

Expression of the Wilms' tumor gene WT1 in primary astrocytic tumors was examined using a quantitative real‐time reverse transcriptase‐polymerase chain reaction (RT‐PCR) or immunohistochemistry. Real‐time RT‐PCR showed that WT1 mRNA was expressed at various levels in all of the 25 astrocytic tumors examined. Immunohistochemical analysis showed that WT1 protein was expressed in 5 of 6 low‐grade astrocytic tumors (grade l‐ll) and all of 18 high‐grade ones (grade III‐IV), and that expression levels of WT1 protein in high‐grade tumors were significantly higher than those in low‐grade ones. WT1 protein was not detected in the normal glial cells contained in the tumor specimens. Furthermore, treatment with WT1 antisense oligomers specifically inhibited growth of glioblastoma cell lines, U87‐MG, A172, and T‐98G. These results may indicate that the WT1 gene plays an important role in tumorigenesis of primary astrocytic tumors.

[1]  I. Kawase,et al.  Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis , 2003, International journal of hematology.

[2]  X. Xia,et al.  Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. , 1993, The Journal of biological chemistry.

[3]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.

[4]  Y. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer , 2003, Cancer science.

[5]  C. B. Patel,et al.  Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. , 2001, Cancer research.

[6]  D. Bonthron,et al.  Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Tsuboi,et al.  WT1 as a novel target antigen for cancer immunotherapy. , 2002, Current cancer drug targets.

[8]  S. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers , 2002, International journal of cancer.

[9]  D. Bigner,et al.  Specific chromosomal abnormalities in malignant human gliomas. , 1988, Cancer research.

[10]  Peter J. Smith,et al.  Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors , 2002, International journal of cancer.

[11]  Y. Oji,et al.  Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth , 1999, Japanese journal of cancer research : Gann.

[12]  S M Hewitt,et al.  Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.

[13]  A. Poustka,et al.  Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping , 1990, Nature.

[14]  T. Kudoh,et al.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.

[15]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[16]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[17]  K. Aozasa,et al.  Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product1 , 2000, The Journal of Immunology.

[18]  H. Sugiyama.  Cancer Immunotherapy Targeting WT1 Protein , 2002, International journal of hematology.

[19]  Y. Miyoshi,et al.  High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  V. Sukhatme,et al.  Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  V. P. Collins,et al.  CDKN 2 ( p 16 / MTS 1 ) Gene Deletion or CDK 4 Amplification Occurs in the Majority of Glioblastomast , 2006 .

[22]  M. Monden,et al.  Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma , 2003, Cancer science.

[23]  M. Niksic,et al.  The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. , 2003, Human molecular genetics.

[24]  Y. Miyoshi,et al.  Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer. , 2004, Japanese journal of clinical oncology.

[25]  Yoshifumi Yamamoto,et al.  Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma , 2003, Cancer science.

[26]  Y. Oji,et al.  Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). , 1999, Leukemia research.

[27]  G I Bell,et al.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. , 1992, Science.

[28]  S. Miyoshi,et al.  Absence of mutations in the Wilms' tumor gene wt1 in de novo non-small cell lung cancers. , 2004, Neoplasma.

[29]  L. Muhlbaier,et al.  Specific Chromosomal Abnormalities in Malignant Human Gliomas1 , 2006 .

[30]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[31]  J. Pelletier,et al.  Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. , 1995, Oncogene.

[32]  Okuyama,et al.  WT1 Gene Expression in Human Testicular Germ-Cell Tumors. , 1999, Molecular urology.

[33]  P. Smith,et al.  A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. , 1996, Oncogene.

[34]  H. Yoshikawa,et al.  Overexpression of the Wilms' tumor gene WT1 in human bone and soft‐tissue sarcomas , 2003, Cancer science.

[35]  I. Kawase,et al.  Monitoring Minimal Residual Disease in Leukemia Using Real-time Quantitative Polymerase Chain Reaction for Wilms Tumor Gene (WT1) , 2003, International journal of hematology.

[36]  I. Kawase,et al.  WT1 Peptide‐Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases , 2004, Microbiology and immunology.

[37]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[38]  D. Housman,et al.  WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour , 1991, Nature.

[39]  Y. Oji,et al.  Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. , 1998, Blood.

[40]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.